PCM Trials Acquires EmVenio Research
Effective immediately, the acquisition strengthens both organizations’ abilities to recruit and retain diverse populations for clinical trials.
PCM Trials has announced the acquisition of EmVenio Research, according to a press release.1 Effective immediately, the acquisition strengthens PCM Trials' and EmVenio's abilities to recruit and retain diverse populations for clinical research studies, as required for regulatory approval. Following the acquisition, PCM Trials now has access to a site network that is focused on serving underrepresented patient populations in previously hard-to-reach communities and can work flexibly with sponsors to achieve their study goals.
"The acquisition of EmVenio is an important part of our company's overall strategy to further remove barriers for patients of all backgrounds and ethnicities to participate in clinical research, creating the most patient-centric clinical trial model," said Greg Austin, president of PCM Trials in the press release. "Our pioneering approach to using Certified Mobile Research Nurses who visit patients in their homes has already been shown to improve both patient retention and diversity in clinical trials and drive faster study completion. Now, with the addition of EmVenio's mobile research site network, we have the unmatched ability to provide additional convenience for prospective participants, empowering community-based clinical trial access."
EmVenio has activated 63 mobile sites across over 22 states in the United States plus 10 locations in the United Kingdom. Additionally, the community-based clinical trial site provider has contracted 25 studies across numerous therapeutic areas.
This most recent acquisition of EmVenio marks the second completed by PCM Trials within the past month. On January 10, the company announced the acquisition of Netherlands-based Clinical Trial Service (CTS), which solidified PCM Trials' ability and reach to successfully conduct global clinical trials.2
"We are thrilled to announce the culmination of EmVenio's and PCM Trials' efforts in creating the most comprehensive global capability for patient visits, spanning from traditional site settings to the comfort of one's home, and everywhere in between through mobile sites," said Thad Wolfram, president of EmVenio in the press release. "Our combined services prioritize minimizing burdens for research participation while enhancing the overall participant experience."
References
1. PCM Trials Acquires EmVenio Research to Create the Most Patient-Centric Model for Hybrid and Decentralized Clinical Trials. News release. February 23, 2024. Accessed March 13, 2024. https://www.prnewswire.com/news-releases/pcm-trials-acquires-emvenio-research-to-create-the-most-patient-centric-model-for-hybrid-and-decentralized-clinical-trials-302070059.html
2. PCM Trials Acquires Netherlands-Based Clinical Trial Service B.V., Becoming the Most Experienced Independent Provider of Mobile Visit Services with The Largest Geographic Coverage Area in Support of Decentralized Clinical Trials. News release. January 10, 2024. Accessed March 13, 2024. https://www.prnewswire.com/news-releases/pcm-trials-acquires-netherlands-based-clinical-trial-service-bv-becoming-the-most-experienced-independent-provider-of-mobile-visit-services-with-the-largest-geographic-coverage-area-in-support-of-decentralized-clinical-trials-302030478.html
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
FOCUS Trial Results Show Solriamfetol Significantly Reduces ADHD Symptoms, Severity in Adults
March 27th 2025Solriamfetol achieved the primary and key secondary endpoint of the Phase III FOCUS trial by significantly lowering attention-deficit hyperactivity disorder symptoms and disease severity in adults compared to placebo, with a favorable safety and tolerability profile.
